Your browser doesn't support javascript.
loading
Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma.
Bararia, Deepak; Hildebrand, Johannes A; Stolz, Sebastian; Haebe, Sarah; Alig, Stefan; Trevisani, Christopher P; Osorio-Barrios, Francisco; Bartoschek, Michael D; Mentz, Michael; Pastore, Alessandro; Gaitzsch, Erik; Heide, Michael; Jurinovic, Vindi; Rautter, Katharina; Gunawardana, Jay; Sabdia, Muhammed B; Szczepanowski, Monika; Richter, Julia; Klapper, Wolfram; Louissaint, Abner; Ludwig, Christina; Bultmann, Sebastian; Leonhardt, Heinrich; Eustermann, Sebastian; Hopfner, Karl-Peter; Hiddemann, Wolfgang; von Bergwelt-Baildon, Michael; Steidl, Christian; Kridel, Robert; Tobin, Joshua W D; Gandhi, Maher K; Weinstock, David M; Schmidt-Supprian, Marc; Sárosi, Menyhárt B; Rudelius, Martina; Passerini, Verena; Mautner, Josef; Weigert, Oliver.
Afiliação
  • Bararia D; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden
  • Hildebrand JA; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden
  • Stolz S; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany.
  • Haebe S; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany.
  • Alig S; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany.
  • Trevisani CP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Osorio-Barrios F; Institute of Experimental Hematology, TranslaTUM, Klinikum rechts der Isar, Technical University of Munich, Munich, Bavaria 81675, Germany.
  • Bartoschek MD; Department of Biology II, Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany.
  • Mentz M; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany.
  • Pastore A; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Gaitzsch E; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden
  • Heide M; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden
  • Jurinovic V; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; Institute for Medical Information Processing, Biometry, and Epidemiology, Munich, Bavaria 81377, Germany.
  • Rautter K; Immunoanalytics: Research Group Tissue Control of Immunocytes & Core Facility, German Research Center for Environmental Health, Helmholtz Zentrum München, Munich, Bavaria 81377, Germany.
  • Gunawardana J; Blood Cancer Research Group, Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD 4101, Australia.
  • Sabdia MB; Blood Cancer Research Group, Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD 4101, Australia.
  • Szczepanowski M; Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein 24105, Germany.
  • Richter J; Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein 24105, Germany.
  • Klapper W; Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-Holstein 24105, Germany.
  • Louissaint A; Massachusetts General Hospital, Department of Pathology, Boston, MA 02114, USA.
  • Ludwig C; Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), Technical University of Munich, Munich, Bavaria 85354, Germany.
  • Bultmann S; Department of Biology II, Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany.
  • Leonhardt H; Department of Biology II, Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany.
  • Eustermann S; Gene Center, Ludwig-Maximilians-University, Munich, Bavaria 81377, Germany.
  • Hopfner KP; Gene Center, Ludwig-Maximilians-University, Munich, Bavaria 81377, Germany.
  • Hiddemann W; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden
  • von Bergwelt-Baildon M; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden
  • Steidl C; Center for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC V5Z 1L3, Canada.
  • Kridel R; Center for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC V5Z 1L3, Canada.
  • Tobin JWD; Blood Cancer Research Group, Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD 4101, Australia.
  • Gandhi MK; Blood Cancer Research Group, Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD 4101, Australia.
  • Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Schmidt-Supprian M; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; Institute of Experimental Hematology, TranslaTUM, Klinikum rechts der Isar, Technical University of Munich, Munich, Bavaria 81675, Germany.
  • Sárosi MB; Institute of Inorganic Chemistry, Faculty of Chemistry and Mineralogy, Leipzig University, Leipzig, Saxony 04103, Germany.
  • Rudelius M; Institute of Pathology, Ludwig-Maximilians-University (LMU), Munich, Bavaria 80337, Germany.
  • Passerini V; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden
  • Mautner J; Helmholtz Zentrum München & Techniqual University of Munich, Munich, Bavaria 81377, Germany.
  • Weigert O; Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Hospital of the Ludwig-Maximilians-University (LMU), Munich, Bavaria 81377, Germany; German Cancer Consortium (DKTK), Munich, Bavaria 81377, Germany; German Cancer Research Center (DKFZ), Heidelberg, Baden
Cell Rep ; 31(5): 107522, 2020 05 05.
Article em En | MEDLINE | ID: mdl-32330423
ABSTRACT
Tumor cells orchestrate their microenvironment. Here, we provide biochemical, structural, functional, and clinical evidence that Cathepsin S (CTSS) alterations induce a tumor-promoting immune microenvironment in follicular lymphoma (FL). We found CTSS mutations at Y132 in 6% of FL (19/305). Another 13% (37/286) had CTSS amplification, which was associated with higher CTSS expression. CTSS Y132 mutations lead to accelerated autocatalytic conversion from an enzymatically inactive profrom to active CTSS and increased substrate cleavage, including CD74, which regulates major histocompatibility complex class II (MHC class II)-restricted antigen presentation. Lymphoma cells with hyperactive CTSS more efficiently activated antigen-specific CD4+ T cells in vitro. Tumors with hyperactive CTSS showed increased CD4+ T cell infiltration and proinflammatory cytokine perturbation in a mouse model and in human FLs. In mice, this CTSS-induced immune microenvironment promoted tumor growth. Clinically, patients with CTSS-hyperactive FL had better treatment outcomes with standard immunochemotherapies, indicating that these immunosuppressive regimens target both the lymphoma cells and the tumor-promoting immune microenvironment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Catepsinas / Linfoma Folicular / Apresentação de Antígeno / Microambiente Tumoral Limite: Animals / Humans Idioma: En Revista: Cell Rep Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Catepsinas / Linfoma Folicular / Apresentação de Antígeno / Microambiente Tumoral Limite: Animals / Humans Idioma: En Revista: Cell Rep Ano de publicação: 2020 Tipo de documento: Article